Welsh Government has approved advice from the All Wales Medicines Strategy Group (AWMSG) for three medicines.
- Indacaterol acetate/glycopyrronium bromide/mometasone furoate (Enerzair® Breezhaler®) was recommended as an option for the maintenance treatment of asthma in adults.
- Perampanel (Fycompa®) was recommended for use as an add-on to other anti-epileptic medicines for the treatment of partial-onset seizures with or without secondarily generalised seizures in children aged 4 years to under 12 years, but only when the seizures are uncontrolled with the first use of combination anti-epileptic therapy.
- Conestat alfa (Ruconest®) is recommended as an option to treat attacks of acute angioedema in children aged 2 years and older who have hereditary angioedema (HAE) caused by a lack of C1 esterase inhibitor. Conestat alfa is already used to treat attacks of acute angioedema in adolescents and adults with HAE.
AWTTC’s Patient Access to Medicines Service (PAMS) supports the AWMSG to assess and monitor new medicines in Wales.